Nature's Sunshine Products (NATR) Stock Price, News & Analysis

Company Overview

Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.

Key Stats

• Today's Range: $13.84 to $14.50
• 50-Day Range: $13.86 to $15.70
• 52-Week Range: $10.81 to $21.72
• Volume: 17,948 shs
• Average Volume: 20,822 shs
• Market Capitalization: $257.43 million
• P/E Ratio: 15.83
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Buy

Nature's Sunshine Products Stock Analysis - MarketRank™

Nature's Sunshine Products scored higher than 74% of companies evaluated by MarketBeat, and ranked 251st out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nature's Sunshine Products has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nature's Sunshine Products has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nature's Sunshine Products is 15.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nature's Sunshine Products is 15.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 17.60.

Price to Book Value per Share Ratio

Nature's Sunshine Products has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.51% of the float of Nature's Sunshine Products has been sold short.

Short Interest Ratio / Days to Cover

Nature's Sunshine Products has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nature's Sunshine Products has recently decreased by 17.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nature's Sunshine Products does not currently pay a dividend.

Dividend Growth

Nature's Sunshine Products does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.51% of the float of Nature's Sunshine Products has been sold short.

Short Interest Ratio / Days to Cover

Nature's Sunshine Products has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nature's Sunshine Products has recently decreased by 17.46%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Nature's Sunshine Products has a news sentiment score of 1.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Nature's Sunshine Products this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for NATR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nature's Sunshine Products insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of Nature's Sunshine Products is held by insiders.

Percentage Held by Institutions

79.40% of the stock of Nature's Sunshine Products is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NATR Stock Analysis - Frequently Asked Questions

How have NATR shares performed this year?

Nature's Sunshine Products' stock was trading at $14.66 at the start of the year. Since then, NATR shares have decreased by 5.0% and is now trading at $13.93.
View the best growth stocks for 2025 here.

How were Nature's Sunshine Products' earnings last quarter?

Nature's Sunshine Products, Inc. (NASDAQ:NATR) announced its earnings results on Thursday, November, 7th. The company reported $0.27 earnings per share for the quarter. The business earned $114.62 million during the quarter. Nature's Sunshine Products had a trailing twelve-month return on equity of 11.08% and a net margin of 3.81%.

Who are Nature's Sunshine Products' major shareholders?

Nature's Sunshine Products' top institutional shareholders include Fosun International Ltd (15.79%), Dimensional Fund Advisors LP (4.64%), Paradigm Capital Management Inc. NY (4.43%) and Renaissance Technologies LLC (2.93%). Insiders that own company stock include Wynnefield Partners Small Cap, Bryant J Yates, Daniel C Norman, Fosun Pharmaceutical Shanghai and Nathan G Brower.
View institutional ownership trends.

How do I buy shares of Nature's Sunshine Products?

Shares of NATR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nature's Sunshine Products own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nature's Sunshine Products investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Meta Platforms (META) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/20/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Personal Products
• Current Symbol: NASDAQ:NATR
• CUSIP: 63902710
• CIK: 275053
• Web: www.naturessunshine.com
• Phone: (801) 341-7900
• Fax: 801-342-4305
• Employees: 850
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $19.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $18.00
• Potential Upside/Downside: +36.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.88
• Trailing P/E Ratio: 15.83
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $15.08 million
• Net Margins: 3.81%
• Pretax Margin: 5.54%
• Return on Equity: 11.08%
• Return on Assets: 7.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.44
• Quick Ratio: 1.51

Sales & Book Value

• Annual Sales: $445.32 million
• Price / Sales: 0.58
• Cash Flow: $1.55 per share
• Price / Cash Flow: 9.01
• Book Value: $8.36 per share
• Price / Book: 1.67

Miscellaneous

• Outstanding Shares: 18,480,000
• Free Float: 17,608,000
• Market Cap: $257.43 million
• Optionable: Optionable
• Beta: 0.96